-
Something wrong with this record ?
The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles
J Myslivecek, M Klein, M Novakova, J Ricny
Language English Country Germany
NLK
SpringerLink Journals
from 1997-01-01 to 2009-04-30
ProQuest Central
from 2007-01-01 to 2009-12-31
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2007-01-01 to 2009-12-31
- MeSH
- Gene Expression MeSH
- Financing, Organized MeSH
- Type C Phospholipases metabolism MeSH
- Binding, Competitive MeSH
- Rats MeSH
- Rats, Wistar MeSH
- Receptor, Muscarinic M1 metabolism drug effects MeSH
- Receptor, Muscarinic M2 metabolism drug effects MeSH
- Receptor, Muscarinic M3 metabolism drug effects MeSH
- Receptor, Muscarinic M5 metabolism drug effects MeSH
- Receptors, Muscarinic metabolism drug effects MeSH
- Heart Ventricles metabolism drug effects MeSH
- Heart Atria metabolism drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
Mammal heart tissue has long been assumed to be the exclusive domain of the M(2) subtype of muscarinic receptor, but data supporting the presence of other subtypes also exist. We have tested the hypothesis that muscarinic receptors other than the M(2) subtype are present in the heart as minor populations. We used several approaches: a set of competition binding experiments with pirenzepine, AFDX-116, 4-DAMP, PD 102807, p-F-HHSiD, AQ-RA 741, DAU 5884, methoctramine and tripinamide, blockage of M(1) muscarinic receptors using MT7 toxin, subtype-specific immunoprecipitation experiments and determination of phospholipase C activity. We also attempted to block M(1)-M(4) receptors using co-treatment with MT7 and AQ-RA 741. Our results show that only the M(2) subtype is present in the atria. In the ventricles, however, we were able to determine that 20% (on average) of the muscarinic receptors were subtypes other than M(2), with the majority of these belonging to the M(1) subtype. We were also able to detect a marginal fraction (6 +/- 2%) of receptors that, based on other findings, belong mainly to the M(5) muscarinic receptors. Co-treatment with MT7 and AQ-RA 741 was not a suitable tool for blocking of M(1)-M(4) receptors and can not therefore be used as a method for M(5) muscarinic receptor detection in substitution to crude venom. These results provide further evidence of the expression of the M(1) muscarinic receptor subtype in the rat heart and also show that the heart contains at least one other, albeit minor, muscarinic receptor population, which most likely belongs to the M(5) muscarinic receptors but not to that of the M(3) receptors.
References provided by Crossref.org
- 000
- 03712naa 2200493 a 4500
- 001
- bmc11006715
- 003
- CZ-PrNML
- 005
- 20121101093818.0
- 008
- 110405s2008 gw e eng||
- 009
- AR
- 024 __
- $a 10.1007/s00210-008-0285-8 $2 doi
- 035 __
- $a (PubMed)18443764
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Mysliveček, Jaromír, $d 1968- $7 nlk19990073583
- 245 14
- $a The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles / $c J Myslivecek, M Klein, M Novakova, J Ricny
- 314 __
- $a Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 5, 12800, Prague, Czech Republic. jmys@lf1.cuni.cz
- 520 9_
- $a Mammal heart tissue has long been assumed to be the exclusive domain of the M(2) subtype of muscarinic receptor, but data supporting the presence of other subtypes also exist. We have tested the hypothesis that muscarinic receptors other than the M(2) subtype are present in the heart as minor populations. We used several approaches: a set of competition binding experiments with pirenzepine, AFDX-116, 4-DAMP, PD 102807, p-F-HHSiD, AQ-RA 741, DAU 5884, methoctramine and tripinamide, blockage of M(1) muscarinic receptors using MT7 toxin, subtype-specific immunoprecipitation experiments and determination of phospholipase C activity. We also attempted to block M(1)-M(4) receptors using co-treatment with MT7 and AQ-RA 741. Our results show that only the M(2) subtype is present in the atria. In the ventricles, however, we were able to determine that 20% (on average) of the muscarinic receptors were subtypes other than M(2), with the majority of these belonging to the M(1) subtype. We were also able to detect a marginal fraction (6 +/- 2%) of receptors that, based on other findings, belong mainly to the M(5) muscarinic receptors. Co-treatment with MT7 and AQ-RA 741 was not a suitable tool for blocking of M(1)-M(4) receptors and can not therefore be used as a method for M(5) muscarinic receptor detection in substitution to crude venom. These results provide further evidence of the expression of the M(1) muscarinic receptor subtype in the rat heart and also show that the heart contains at least one other, albeit minor, muscarinic receptor population, which most likely belongs to the M(5) muscarinic receptors but not to that of the M(3) receptors.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kompetitivní vazba $7 D001667
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a srdeční síně $x metabolismus $x účinky léků $7 D006325
- 650 _2
- $a srdeční komory $x metabolismus $x účinky léků $7 D006352
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptor muskarinový M1 $x metabolismus $x účinky léků $7 D043643
- 650 _2
- $a receptor muskarinový M2 $x metabolismus $x účinky léků $7 D043585
- 650 _2
- $a receptor muskarinový M3 $x metabolismus $x účinky léků $7 D043587
- 650 _2
- $a receptor muskarinový M5 $x metabolismus $x účinky léků $7 D043642
- 650 _2
- $a receptory muskarinové $x metabolismus $x účinky léků $7 D011976
- 650 _2
- $a fosfolipasy typu C $x metabolismus $7 D010738
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Klein, Martin $7 xx0092749
- 700 1_
- $a Nováková, Martina. $7 _AN029770
- 700 1_
- $a Říčný, Jan $7 xx0153151
- 773 0_
- $t Naunyn-Schmiedebergs Archives of Pharmacology $w MED00003462 $g Roč. 378, č. 1 (2008), s. 103-116 $x 0028-1298
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20110412125434 $b ABA008
- 991 __
- $a 20121101093822 $b ABA008
- 999 __
- $a ok $b bmc $g 834339 $s 698831
- BAS __
- $a 3
- BMC __
- $a 2008 $b 378 $c 1 $d 103-116 $i 0028-1298 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
- LZP __
- $a 2011-4B/ewme